Thoms, Kai-Martin

[["dc.bibliographiccitation.firstpage","3359"],["dc.bibliographiccitation.issue","13"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.affiliation","Koch, Elias; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, elias.koch@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, elias.koch@uk-erlangen.de"],["dc.contributor.affiliation","Petzold, Anne; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Anne.Petzold@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, Anne.Petzold@uk-erlangen.de"],["dc.contributor.affiliation","Wessely, Anja; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Anja.Wessely@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, Anja.Wessely@uk-erlangen.de"],["dc.contributor.affiliation","Dippel, Edgar; \t\t \r\n\t\t Department of Dermatology, Ludwigshafen Medical Center, 67059 Ludwigshafen, Germany, dippele@klilu.de"],["dc.contributor.affiliation","Gesierich, Anja; \t\t \r\n\t\t Department of Dermatology, University Hospital Würzburg, 97080 Würzburg, Germany, gesierich_a@ukw.de"],["dc.contributor.affiliation","Gutzmer, Ralf; \t\t \r\n\t\t Skin Cancer Center Minden, Department of Dermatology, Mühlenkreiskliniken AöR, Ruhr University Bochum Campus Minden, 32423 Minden, Germany, Ralf.Gutzmer@ruhr-uni-bochum.de"],["dc.contributor.affiliation","Hassel, Jessica; \t\t \r\n\t\t Skin Cancer Center, Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, 69120 Heidelberg, Germany, Jessica.Hassel@med.uni-heidelberg.de"],["dc.contributor.affiliation","Haferkamp, Sebastian; \t\t \r\n\t\t Department of Dermatology, University Hospital Regensburg, 93053 Regensburg, Germany, sebastian.haferkamp@ukr.de"],["dc.contributor.affiliation","Hohberger, Bettina; \t\t \r\n\t\t Department of Ophthalmology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Bettina.Hohberger@uk-erlangen.de"],["dc.contributor.affiliation","Kähler, Katharina; \t\t \r\n\t\t Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany, kckaehler@yahoo.de"],["dc.contributor.affiliation","Knorr, Harald; \t\t \r\n\t\t Department of Ophthalmology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Harald.Knorr@uk-erlangen.de"],["dc.contributor.affiliation","Kreuzberg, Nicole; \t\t \r\n\t\t Department of Dermatology and Venereology, Skin Cancer Center at the Center of Integrated Oncology (CIO) Köln Bonn, University Hospital of Cologne, 50937 Cologne, Germany, nicole.kreuzberg@uk-koeln.de"],["dc.contributor.affiliation","Leiter, Ulrike; \t\t \r\n\t\t Department of Dermatology, Center for Dermatooncology, University Hospital Tübingen, 72056 Tübingen, Germany, Ulrike.Leiter@med.uni-tuebingen.de"],["dc.contributor.affiliation","Loquai, Carmen; \t\t \r\n\t\t Department of Dermatology, University Medical Center Mainz, 55131 Mainz, Germany, carmen.loquai@unimedizin-mainz.de"],["dc.contributor.affiliation","Meier, Friedegund; \t\t \r\n\t\t Skin Cancer Center at the University Cancer Centre Dresden and National Center for Tumor Diseases & Department of Dermatology, University Hospital Carl Gustav Carus, 01307 Dresden, Germany, Friedegund.Meier@uniklinikum-dresden.de"],["dc.contributor.affiliation","Meissner, Markus; \t\t \r\n\t\t Department of Dermatology, Venereology and Allergology, Goethe University, 60590 Frankfurt am Main, Germany, markus.meissner@kgu.de"],["dc.contributor.affiliation","Mohr, Peter; \t\t \r\n\t\t Department of Dermatology, Elbeklinikum, 21614 Buxtehude, Germany, peter.mohr@elbekliniken.de"],["dc.contributor.affiliation","Pföhler, Claudia; \t\t \r\n\t\t Department of Dermatology, Saarland University Medical School, 66421 Homburg/Saar, Germany, claudia.pfoehler@uks.eu"],["dc.contributor.affiliation","Rahimi, Farnaz; \t\t \r\n\t\t Department of Dermatology and Allergy, Munich University Hospital (LMU), 81377 Munich, Germany, Farnaz.Rahimi@med.uni-muenchen.de"],["dc.contributor.affiliation","Schadendorf, Dirk; \t\t \r\n\t\t Department of Dermatology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany, Dirk.Schadendorf@uk-essen.de\t\t \r\n\t\t German Cancer Consortium, Partner Site Essen, 45147 Essen, Germany, Dirk.Schadendorf@uk-essen.de"],["dc.contributor.affiliation","Schell, Beatrice; \t\t \r\n\t\t Department of Dermatology, SRH Wald-Klinikum Gera, 07548 Gera, Germany, Beatrice.Schell@srh.de"],["dc.contributor.affiliation","Schlaak, Max; \t\t \r\n\t\t Department of Dermatology, Venerology and Allergology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, 10117 Berlin, Germany, max.schlaak@charite.de"],["dc.contributor.affiliation","Terheyden, Patrick; \t\t \r\n\t\t Department of Dermatology, University of Lübeck, 23562 Lübeck, Germany, patrick.terheyden@uksh.de"],["dc.contributor.affiliation","Thoms, Kai-Martin; \t\t \r\n\t\t Department of Dermatology, University Medical Center Goettingen, 37075 Goettingen, Germany, kai.thoms@med.uni-goettingen.de"],["dc.contributor.affiliation","Schuler-Thurner, Beatrice; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Beatrice.Schuler-Thurner@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, Beatrice.Schuler-Thurner@uk-erlangen.de"],["dc.contributor.affiliation","Ugurel, Selma; \t\t \r\n\t\t Department of Dermatology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany, Selma.Ugurel@uk-essen.de"],["dc.contributor.affiliation","Ulrich, Jens; \t\t \r\n\t\t Department of Dermatology, Harzklinikum Dorothea Christiane Erxleben, 06484 Quedlinburg, Germany, jens.ulrich@harzklinikum.com"],["dc.contributor.affiliation","Utikal, Jochen; \t\t \r\n\t\t Skin Cancer Unit, German Cancer Research Center (DKFZ), 68167 Heidelberg, Germany, Jochen.Utikal@umm.de\t\t \r\n\t\t Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, 68167 Mannheim, Germany, Jochen.Utikal@umm.de"],["dc.contributor.affiliation","Weichenthal, Michael; \t\t \r\n\t\t Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany, mweichenthal@dermatology.uni-kiel.de"],["dc.contributor.affiliation","Ziller, Fabian; \t\t \r\n\t\t Department of Dermatology, DRK Krankenhaus Rabenstein, 09117 Chemnitz, Germany, Ziller.Fabian@drk-khs.de"],["dc.contributor.affiliation","Berking, Carola; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Carola.Berking@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, Carola.Berking@uk-erlangen.de"],["dc.contributor.affiliation","Heppt, Markus; \t\t \r\n\t\t Department of Dermatology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany, Markus.Heppt@uk-erlangen.de\t\t \r\n\t\t Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), 91054 Erlangen, Germany, Markus.Heppt@uk-erlangen.de"],["dc.contributor.author","Koch, Elias"],["dc.contributor.author","Petzold, Anne"],["dc.contributor.author","Wessely, Anja"],["dc.contributor.author","Dippel, Edgar"],["dc.contributor.author","Gesierich, Anja"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Hassel, Jessica"],["dc.contributor.author","Haferkamp, Sebastian"],["dc.contributor.author","Hohberger, Bettina"],["dc.contributor.author","Heppt, Markus"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Kähler, Katharina"],["dc.contributor.author","Knorr, Harald"],["dc.contributor.author","Kreuzberg, Nicole"],["dc.contributor.author","Leiter, Ulrike"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Meier, Friedegund"],["dc.contributor.author","Meissner, Markus"],["dc.contributor.author","Mohr, Peter"],["dc.contributor.author","Pföhler, Claudia"],["dc.contributor.author","Rahimi, Farnaz"],["dc.contributor.author","Schadendorf, Dirk"],["dc.contributor.author","Schell, Beatrice"],["dc.contributor.author","Schlaak, Max"],["dc.contributor.author","Terheyden, Patrick"],["dc.contributor.author","Schuler-Thurner, Beatrice"],["dc.contributor.author","Ugurel, Selma"],["dc.contributor.author","Ulrich, Jens"],["dc.contributor.author","Utikal, Jochen"],["dc.contributor.author","Weichenthal, Michael"],["dc.contributor.author","Ziller, Fabian"],["dc.contributor.author","Berking, Carola"],["dc.contributor.authorgroup","on behalf of the German Dermatologic Cooperative Oncology Group (DeCOG, Committee Ocular Melanoma)"],["dc.date.accessioned","2021-08-12T07:45:52Z"],["dc.date.available","2021-08-12T07:45:52Z"],["dc.date.issued","2021"],["dc.date.updated","2022-02-09T13:20:46Z"],["dc.description.abstract","Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ2 tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only."],["dc.description.abstract","Background: Since there is no standardized and effective treatment for advanced uveal melanoma (UM), the prognosis is dismal once metastases develop. Due to the availability of immune checkpoint blockade (ICB) in the real-world setting, the prognosis of metastatic UM has improved. However, it is unclear how the presence of hepatic and extrahepatic metastasis impacts the response and survival after ICB. Methods: A total of 178 patients with metastatic UM treated with ICB were included in this analysis. Patients were recruited from German skin cancer centers and the German national skin cancer registry (ADOReg). To investigate the impact of hepatic metastasis, two cohorts were compared: patients with liver metastasis only (cohort A, n = 55) versus those with both liver and extra-hepatic metastasis (cohort B, n = 123). Data were analyzed in both cohorts for response to treatment, progression-free survival (PFS), and overall survival (OS). The survival and progression probabilities were calculated with the Kaplan–Meier method. Log-rank tests, χ2 tests, and t-tests were performed to detect significant differences between both cohorts. Results: The median OS of the overall population was 16 months (95% CI 13.4–23.7) and the median PFS, 2.8 months (95% CI 2.5–3.0). The median OS was longer in cohort B than in cohort A (18.2 vs. 6.1 months; p = 0.071). The best objective response rate to dual ICB was 13.8% and to anti-PD-1 monotherapy 8.9% in the entire population. Patients with liver metastases only had a lower response to dual ICB, yet without significance (cohort A 8.7% vs. cohort B 16.7%; p = 0.45). Adverse events (AE) occurred in 41.6%. Severe AE were observed in 26.3% and evenly distributed between both cohorts. Conclusion: The survival of this large cohort of patients with advanced UM was more favorable than reported in previous benchmark studies. Patients with both hepatic and extrahepatic metastasis showed more favorable survival and higher response to dual ICB than those with hepatic metastasis only."],["dc.identifier.doi","10.3390/cancers13133359"],["dc.identifier.eissn","2072-6694"],["dc.identifier.pii","cancers13133359"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/88565"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-448"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","582"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal der Deutschen Dermatologischen Gesellschaft"],["dc.bibliographiccitation.lastpage","609"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Kähler, Katharina C."],["dc.contributor.author","Hassel, Jessica C."],["dc.contributor.author","Heinzerling, Lucie"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Thoms, Kai‐Martin"],["dc.contributor.author","Ugurel, Selma"],["dc.contributor.author","Zimmer, Lisa"],["dc.contributor.author","Gutzmer, Ralf"],["dc.date.accessioned","2021-04-14T08:25:27Z"],["dc.date.available","2021-04-14T08:25:27Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1111/ddg.14128"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81631"],["dc.language.iso","de"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1610-0387"],["dc.relation.issn","1610-0379"],["dc.title","Side effect management during immune checkpoint blockade using CTLA‐4 and PD‐1 antibodies for metastatic melanoma – an update"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","12"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","23"],["dc.bibliographiccitation.volume","106"],["dc.contributor.author","Moreira, Alvaro"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Pföhler, Claudia"],["dc.contributor.author","Kähler, Katharina C."],["dc.contributor.author","Knauss, Samuel"],["dc.contributor.author","Heppt, Markus V."],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Dimitriou, Florentia"],["dc.contributor.author","Meier, Friedegund"],["dc.contributor.author","Mitzel-Rink, Heidrun"],["dc.contributor.author","Schuler, Gerold"],["dc.contributor.author","Terheyden, Patrick"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Türk, Matthias"],["dc.contributor.author","Dummer, Reinhard"],["dc.contributor.author","Zimmer, Lisa"],["dc.contributor.author","Schröder, Rolf"],["dc.contributor.author","Heinzerling, Lucie"],["dc.date.accessioned","2020-12-10T14:23:39Z"],["dc.date.available","2020-12-10T14:23:39Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1016/j.ejca.2018.09.033"],["dc.identifier.issn","0959-8049"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72002"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1435"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","International Journal of Cancer"],["dc.bibliographiccitation.lastpage","1442"],["dc.bibliographiccitation.volume","129"],["dc.contributor.author","Kretschmer, Lutz"],["dc.contributor.author","Starz, Hans"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Satzger, Imke"],["dc.contributor.author","Voelker, Bernward"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Mitteldorf, Christina"],["dc.contributor.author","Bader, Claudia"],["dc.contributor.author","Siedlecki, Katharina"],["dc.contributor.author","Kapp, Alexander"],["dc.contributor.author","Bertsch, Hans Peter"],["dc.contributor.author","Gutzmer, Ralf"],["dc.date.accessioned","2018-11-07T08:51:44Z"],["dc.date.available","2018-11-07T08:51:44Z"],["dc.date.issued","2011"],["dc.description.abstract","In our study, we investigated the impact of the constitutional factor age on the clinical courses of melanoma patients with sentinel lymph node (SLN) biopsy. Descriptive statistics, Kaplan-Meier estimates, logistic regression analysis and the Cox proportional hazards model were used to study a population of 2,268 consecutive patients from three German melanoma centers. Younger age was significantly related to less advanced primary tumors. Nevertheless, patients younger than 40 years of age had a twofold risk of being SLN-positive (p < 0.000001). Of the young patients with primary melanomas with a thickness of 0.76 mm to 1.0 mm, 19.7% were SLN-positive. Using multivariate analysis, younger age, increasing Breslow thickness, ulceration and male sex were significantly related to a higher probability of SLN-metastasis. During follow-up, older patients displayed a significantly increased risk of in-transit recurrences (p = 0.000002) and lymph node recurrences (p = 0.0004). With respect to melanoma specific overall survival the patient's age was highly significant in the multivariate analysis. The unfavorable effect of being older was significant in the subgroups with positive and negative SLNs. Age remained also significant for the survival after the onset of distant metastases (p = 0.002). In conclusion, the patient's age is a strong and independent predictor of melanoma-specific survival in patients with localized melanomas, in patients with positive SLNs and after the onset of distant metastases. Younger patients have a better prognosis despite their higher probability of SLN metastasis. Older patients are less frequently SLN-positive but have a higher risk of loco-regional recurrence."],["dc.identifier.doi","10.1002/ijc.25747"],["dc.identifier.isi","000293245800019"],["dc.identifier.pmid","21064111"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22008"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","0020-7136"],["dc.title","Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","125"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","132"],["dc.bibliographiccitation.volume","138"],["dc.contributor.author","Salzmann, Martin"],["dc.contributor.author","Leiter, Ulrike"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Zimmer, Lisa"],["dc.contributor.author","Ugurel, Selma"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Enk, Alexander H."],["dc.contributor.author","Hassel, Jessica C."],["dc.date.accessioned","2021-04-14T08:23:28Z"],["dc.date.available","2021-04-14T08:23:28Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1016/j.ejca.2020.07.029"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/80932"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.issn","0959-8049"],["dc.title","Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","158"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Melanoma Research"],["dc.bibliographiccitation.lastpage","164"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Al Ghazal, Philipp"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Satzger, Imke"],["dc.contributor.author","Starz, Hans"],["dc.contributor.author","Bader, Christina"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Mitteldorf, Christina"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Kapp, Alexander"],["dc.contributor.author","Bertsch, Hans-Peter"],["dc.contributor.author","Kretschmer, Lutz"],["dc.date.accessioned","2018-11-07T09:42:15Z"],["dc.date.available","2018-11-07T09:42:15Z"],["dc.date.issued","2014"],["dc.description.abstract","Head or neck location of primary cutaneous melanomas has been described as an adverse prognostic factor, but this has to be reassessed after the introduction of sentinel lymph node (SLN) excision (SLNE). Descriptive statistics, Kaplan-Meier estimates and Cox proportional hazard models were used to study retrospectively a population of 2302 consecutive melanoma patients from three German melanoma centres undergoing SLNE. Approximately 10% of the patients (N=237) had a primary melanoma located at the head or neck (HNM). In both the SLN-positive and SLN-negative subpopulation, patients with HNM were significantly older, more frequently men and had thicker primaries compared with patients with tumours in other locations. The proportion of positive SLNs was lower in HNM compared with other locations of the primary (20 vs. 26%, P=0.048). The false-negative rate was higher in HNM (17.5 vs. 8.4%, P=0.05). In patients with HNM, the SLN status was a significant factor for recurrence-free survival but not for overall survival. SLN-negative HNM patients had a significantly worse overall survival than the SLN negatives with primaries at other sites, whereas the prognosis of the SLN-positive patients was similar in both groups. The prevalence of lymph node metastases after SLNE is lower in patients with HNM compared with other melanoma locations. As a result, the prognostic information provided by the SLN for HNM seems less important. Decision making for SLNE in HNM should be carefully balanced considering the potential morbidity of the procedure."],["dc.identifier.doi","10.1097/CMR.0000000000000042"],["dc.identifier.isi","000332601400009"],["dc.identifier.pmid","24346168"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33915"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1473-5636"],["dc.relation.issn","0960-8931"],["dc.title","Lower prevalence of lymphatic metastasis and poorer survival of the sentinel node-negative patients limit the prognostic value of sentinel node biopsy for head or neck melanomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e000333"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal for Immunotherapy of Cancer"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Amaral, Teresa"],["dc.contributor.author","Kiecker, Felix"],["dc.contributor.author","Schaefer, Sarah"],["dc.contributor.author","Stege, Henner"],["dc.contributor.author","Kaehler, Katharina"],["dc.contributor.author","Terheyden, Patrick"],["dc.contributor.author","Gesierich, Anja"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Haferkamp, Sebastian"],["dc.contributor.author","Uttikal, Jochen"],["dc.contributor.author","Berking, Carola"],["dc.contributor.author","Rafei-Shamsabadi, David"],["dc.contributor.author","Reinhardt, Lydia"],["dc.contributor.author","Meier, Friedegund"],["dc.contributor.author","Karoglan, Ante"],["dc.contributor.author","Posch, Christian"],["dc.contributor.author","Gambichler, Thilo"],["dc.contributor.author","Pfoehler, Claudia"],["dc.contributor.author","Thoms, Kai"],["dc.contributor.author","Tietze, Julia"],["dc.contributor.author","Debus, Dirk"],["dc.contributor.author","Herbst, Rudolf"],["dc.contributor.author","Emmert, Steffen"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Hassel, Jessica C"],["dc.contributor.author","Meiss, Frank"],["dc.contributor.author","Tueting, Thomas"],["dc.contributor.author","Heinrich, Vanessa"],["dc.contributor.author","Eigentler, Thomas"],["dc.contributor.author","Garbe, Claus"],["dc.contributor.author","Zimmer, Lisa"],["dc.date.accessioned","2020-12-10T18:37:15Z"],["dc.date.available","2020-12-10T18:37:15Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1136/jitc-2019-000333"],["dc.identifier.eissn","2051-1426"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/76892"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG study in 380 patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Experimental Dermatology"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Boeckmann, L."],["dc.contributor.author","Thoms, Kai Martin"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Has, Cristina"],["dc.contributor.author","Kunz, M."],["dc.contributor.author","Kuschal, Christiane"],["dc.contributor.author","Laspe, Petra"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Rosenberger, Albert"],["dc.contributor.author","Struever, Diana"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T08:32:03Z"],["dc.date.available","2018-11-07T08:32:03Z"],["dc.date.issued","2009"],["dc.format.extent","311"],["dc.identifier.isi","000263520200230"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17256"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell Publishing, Inc"],["dc.publisher.place","Malden"],["dc.relation.conference","36th Annual Meeting of the Arbeitsgemeinschaft-Dermatologishche-Forschung"],["dc.relation.eventlocation","Heidelberg, GERMANY"],["dc.relation.issn","0906-6705"],["dc.title","DNA repair host factors modulate side effects of temozolomide or dacarbazinemelanoma treatment rather than treatment efficacy and are determined by promoter methylation"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","825"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Cancer Immunology, Immunotherapy"],["dc.bibliographiccitation.lastpage","834"],["dc.bibliographiccitation.volume","67"],["dc.contributor.author","Kähler, Katharina C."],["dc.contributor.author","Eigentler, Thomas K."],["dc.contributor.author","Gesierich, Anja"],["dc.contributor.author","Heinzerling, Lucie"],["dc.contributor.author","Loquai, Carmen"],["dc.contributor.author","Meier, Friedegund"],["dc.contributor.author","Meiss, Frank"],["dc.contributor.author","Pföhler, Claudia"],["dc.contributor.author","Schlaak, Max"],["dc.contributor.author","Terheyden, Patrick"],["dc.contributor.author","Thoms, Kai M."],["dc.contributor.author","Ziemer, Mirjana"],["dc.contributor.author","Zimmer, Lisa"],["dc.contributor.author","Gutzmer, Ralf"],["dc.date.accessioned","2020-12-10T14:09:59Z"],["dc.date.available","2020-12-10T14:09:59Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1007/s00262-018-2134-z"],["dc.identifier.eissn","1432-0851"],["dc.identifier.issn","0340-7004"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70632"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","760"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Pharmacogenetics and Genomics"],["dc.bibliographiccitation.lastpage","769"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Boeckmann, Lars"],["dc.contributor.author","Schirmer, Markus"],["dc.contributor.author","Rosenberger, Albert"],["dc.contributor.author","Struever, Diana"],["dc.contributor.author","Thoms, Kai-Martin"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Has, Cristina"],["dc.contributor.author","Kunz, Manfred"],["dc.contributor.author","Kuschal, Christiane"],["dc.contributor.author","Laspe, Petra"],["dc.contributor.author","Schoen, Michael Peter"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T11:24:01Z"],["dc.date.available","2018-11-07T11:24:01Z"],["dc.date.issued","2009"],["dc.description.abstract","Objectives The efficacy of temozolomide (TMZ) or dacarbazine (DTIC) in melanoma treatment depends on low O-6-methylguanine-DNA-methyltransferase (MGMT) repair and on high mismatch repair. The aim of this study was to identify individual host markers for hematologic side effects and the treatment efficacy of TMZ or DTIC in melanoma treatment. Methods Fifty-one Caucasian patients with metastasized melanoma were recruited. In each patient, the mRNA expression of MGMT and two essential mismatch repair genes, MLH1 and MSH2, was measured in peripheral blood. The coding gene regions, including splice sites, were sequenced to identify genetic variants, and the promoter methylation status of the genes was determined. Results Both constitutively low and high mRNA expression of MGMT, MLH1, and MSH2 were significantly associated with reduced hematologic side effects (P=0.008-0.020), but did not correlate with treatment efficacy. We identified five variants in the MGMT gene, 13 variants in MLH1, and seven variants in MSH2, including five novel genetic variants in MLH1. Variations of the hosts' gene expression of MGMT, MLH1, and MSH2 did not result from promoter methylation. Of note, one variant in MSH2 (rs2303428) was associated with increased hematologic side effects and showed a tendency for better treatment response. Conclusion Our results indicate that either low or high host expression of MGMT, MLH1, and MSH2 may serve as a marker for reduced hematologic side effects of TMZ or DTIC, but not for treatment efficacy in melanoma. The genetic variant rs2303428 (MSH2) might serve as a predictive marker for hematologic side effects and treatment response. Pharmacogenetics and Genomics 19:760-769 (C) 2009 Wolters Kluwer Health "],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft"],["dc.identifier.doi","10.1097/FPC.0b013e3283307cd9"],["dc.identifier.isi","000270467200004"],["dc.identifier.pmid","19741564"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56311"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1744-6872"],["dc.title","Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]